By Hilary Rosselot
Healx Updates the Fragile X Community About their Fragile X Program and the IMPACT-FXS trial
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
Read the full letter to understand the shift in their plans and what to expect: Community statement – Update on IMPACT-FXS
Healx continues to work extensively with the NFXF’s Clinical Trials Committee within the Research Readiness Program to be sure their Fragile X program is scientifically-sound, relevant, and impactful.
Thanks, Healx, for your open and honest communication with the Fragile X community! We look forward to sharing your new study in 2023!
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
PFDD Meeting Community Forum
The Patient-Focused Drug Development (PFDD) meeting on Fragile X syndrome is just around the corner! We need caregivers and self-advocates to participate to make this a valuable meeting. This will help you understand what to expect and what the goal is and how to share your story.
Cortical Gyrification and Its Relationships With Molecular Measures and Cognition in Children With the FMR1 Premutation
Jun Yi Wang and the study team out of the UC Davis MIND Institute are interested in learning more about the premutation carrier condition in relations to brain development and its impact on cognition. These mental processes impact the higher-level functions of the brain including language, learning new things, and making decisions.